| Date | Title | Description | Source |
| 17.11.2023 | Is This European Biotech Startup Revolutionizing Immunothera... | Key Takeaways:
Company: immatics biotechnologies
Industry: Biotechnology, Medical, Therapeutics
Loca... | eustartup.... |
| 11.09.2023 | Moderna and Immatics jointly develop innovative oncology the... | Moderna, Inc. and Immatics N.V. enter into a multi-billion dollar strategic research and development... | bio-m.org/... |
| 24.07.2023 | Immatics Announces $35 Million Equity Investment from Bristo... | - | globenewsw... |
| 17.11.2022 | Immatics veröffentlicht Ergebnisse des dritten Quartals 2022... | Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt h... | einpresswi... |
| 17.11.2022 | Immatics Announces Third Quarter 2022 Financial Results and ... | Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high con... | einpresswi... |
| 10.10.2022 | Immatics Reports Interim Clinical Data Update on ACTengine® ... | Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation... | globenewsw... |
| 10.10.2022 | Immatics Announces $110 Million Underwritten Offering of Ord... | Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), ... | globenewsw... |
| 10.09.2022 | Immatics Presents Comprehensive Preclinical Data Set for TCR... | TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presen... | globenewsw... |
| 23.08.2022 | Immatics Announces First Cancer Patient Treated with Second-... | IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-recepto... | globenewsw... |
| 09.08.2022 | Immatics Announces Second Quarter 2022 Financial Results and... | ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: I... | globenewsw... |
| 07.06.2022 | Immatics und Editas Medicine schließen strategische Forschun... | Tübingen, Deutschland, Houston, Texas und Cambridge, Massachusetts, 7. Juni 2022 – Immatics N.V. (Na... | globenewsw... |
| 02.06.2022 | Immatics Announces First Quarter 2022 Financial Results and ... | ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as we... | globenewsw... |
| 02.06.2022 | Immatics and Bristol Myers Squibb Expand Strategic Alliance ... | New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’... | globenewsw... |
| 18.05.2022 | Immatics Announces First Patient Treated with ACTengine® IMA... | The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor ... | globenewsw... |
| 10.05.2022 | Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead T... | Patient enrollment for IMA401 Phase 1 trial started at first clinical site in GermanyThe study will ... | globenewsw... |
| 23.03.2022 | Immatics Announces Full Year 2021 Financial Results and Corp... | IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different s... | globenewsw... |
| 14.12.2021 | Immatics and Bristol Myers Squibb Enter Into Global Exclusiv... | Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; co... | globenewsw... |
| 14.12.2021 | Immatics and Bristol Myers Squibb Enter Into Global Exclusiv... | Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; co... | marketscre... |
| 16.11.2021 | Immatics Announces Third Quarter 2021 Financial Results and ... | Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinica... | marketscre... |
| 16.11.2021 | Immatics Announces Third Quarter 2021 Financial Results and ... | Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinica... | globenewsw... |
| 09.11.2021 | Immatics Reports Clinical Responses across Multiple Solid Tu... | Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell thera... | globenewsw... |
| 01.11.2021 | Immatics to Present Update on Lead ACTengine® Program IMA203... | Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), ... | globenewsw... |
| 30.03.2021 | IMMATICS N.V.
Press Release: Immatics Announces Full Year 2... | -- Phase 1a data update from clinical ACTengine(R) programs demonstrated first anti-tumor activity a... | marketscre... |
| 18.03.2021 | Immatics N : ACTengine Combined Data Readout presentation Ma... | ACTengine® IMA200 Clinical Trial Series Phase 1a Data Update
Cedrik Britten, Chief Medical Officer ... | marketscre... |
| 17.03.2021 | Immatics Presents Data Update on Dose Escalation from Ongoin... | Company to host conference call on Wednesday, March 17 at 8:30 am EST
·First anti-tumor activity ob... | globenewsw... |
| 28.08.2019 | Immatics and Celgene enter strategic collaboration to develo... | Immatics and Celgene have entered into a strategic collaboration and option agreement to develop nov... | wellington... |
| 28.08.2019 | Celgene invests $75M in cell therapy company Immatics as par... | The deal includes a $75 million investment in the company by Celgene. Immatics would develop TCRs ag... | medcitynew... |
| 08.07.2019 | Immatics appoints Harpreet Singh as Chief Executive Officer | Immatics today announced that Harpreet Singh has been appointed the Company’s Chief Executive Office... | wellington... |
| 27.02.2019 | Immatics announces Clinical Trial Collaboration in Immunothe... | Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, I... | wellington... |
| 17.01.2018 | Immatics appoints Thomas Ulmer as Chief Financial Officer | Immatics today announced the appointment of Thomas Ulmer as Chief Financial Officer, effective April... | wellington... |
| 05.10.2017 | Term Sheet — Thursday, October 5 | LIFE SCIENCES $$$
Good morning, Term Sheet readers.
Paid Content How can you protect what you can'... | fortune.co... |
| 04.10.2017 | Immatics Raises $58M | Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of ... | citybizlis... |
| 04.10.2017 | Immatics Closes $58m Series E Financing Round | Immatics, a Tuebingen, Germany-based cancer immunotherapy company, closed a $58m Series E financing ... | finsmes.co... |
| 04.10.2017 | Amgen helps Immatics to $58M round to fund cancer trials | Immatics has raised $58 million (€49 million) to push its cancer immunotherapies deeper into the cli... | fiercebiot... |
| 04.10.2017 | Immatics Receives $58 Million in Financing to Develop T-Cell... | - | embl-ventu... |
| 04.10.2017 | Amgen helps Immatics to $58M round to fund cancer trials | Immatics has raised $58 million (€49 million) to push its cancer immunotherapies deeper into the cli... | fiercebiot... |
| 04.10.2017 | Immatics receives $58 million in financing to develop T-cell... | Immatics today announced the completion of its Series E financing, raising $58 million. | wellington... |
| 28.09.2017 | Immatics initiates first Phase I clinical trial of ACTengine... | Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201... | wellington... |
| 21.08.2017 | Immatics initiates personalized adoptive cellular therapy in... | Immatics today announced that it has initiated enrolment of patients into a phase I trial of its fir... | wellington... |
| 09.01.2017 | immatics and Amgen sign $1B deal | Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies | wellington... |
| 16.07.2014 | immatics biotechnologies Receives €22M; Completes €34M Serie... | immatics biotechnologies GmbH, a Tuebingen and Martinsried (Munich), Germany-based clinical-stage bi... | finsmes.co... |
| 16.07.2014 | Cancer vaccine maker immatics adds nearly $30M in Series D | Immatics CEO Paul Higham
After scooping up an initial €12 million ($16.2 million) in October and a ... | fiercebiot... |
| 21.11.2013 | With $4.2M raise, Immunovaccine says it’s set through 2014, ... | “Normal vaccines get cleared from site of injection within hours or days. You have to repeatedly vac... | medcitynew... |
| 17.10.2013 | Immatics Closes 34M EURO Series D Round |
MUNICH/TUEBINGEN, GERMANY, Immatics Biotechnologies has closed a 34 million euro Series D financin... | vcnewsdail... |
| 15.10.2013 | immatics biotechnologies Closes €34M Series D Round | immatics biotechnologies GmbH, a German clinical-stage biopharmaceutical company developing advanced... | finsmes.co... |
| 21.09.2010 | immatics biotechnologies Raises €53.8M in Series C Financing... | immatics biotechnologies GmbH, a Tuebingen and Munich, Germany-based biopharmaceutical company devel... | finsmes.co... |
| - | With $4.2M raise, Immunovaccine says it’s set through 2014, ... | Analysts say there’s a multibillion-dollar market up for the taking for companies who figure out how... | medcitynew... |
| - | Celgene invests $75M in cell therapy company Immatics as par... | A large biotech company is pouring tens of millions of dollars into a German firm under a partnershi... | medcitynew... |
